Amicus Therapeutics Announces First Quarter 2017 Financial Results and Corporate Updates
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Amicus Therapeutics (FOLD) Misses Q1 EPS by 3c
May 9, 2017 7:36 AM EDTAmicus Therapeutics (NASDAQ: FOLD) reported Q1 EPS of ($0.39), $0.03 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $4.2 million versus the consensus estimate of $4.16 million.
100+ Fabry Disease Patients Now on Reimbursed Galafold (migalastat) in the EUOn Target to Reach 300... More